Keyword: Wave Life Sciences
In a quiet SEC filing (with no press release) Wave Life Sciences is to cut its staff by nearly a quarter, after a crushing few months.
The results wiped 50% off Wave’s share price, adding to losses it suffered when it dumped a Duchenne muscular dystrophy program earlier in December.
Shares in Wave Life Sciences sunk 50% Monday morning on the news it is throwing out suvodirsen in Duchenne muscular dystrophy.
Asuragen is teaming up with biotech Wave Life Sciences to help develop a new diagnostic for its experimental Huntington’s therapy.
Gilead’s director of oncology clinical research jumps to Compugen, longtime Teva exec becomes Dr. Reddy's COO, Astellas names new ethics & compliance head.
Perennial biotech dealmaker Takeda is at it again, striking a new pact with Wave Life Sciences with a focus on a series of neurological disorders.
Fresh from a major $911 million deal with Pfizer just last month, Wave Life Sciences has seen the FDA grant it an orphan drug designation for its lead candidate WVE-120101.